Kura Oncology (NASDAQ:KURA) Insider Sells $51,662.05 in Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Brian Powl sold 4,345 shares of the company’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $11.89, for a total transaction of $51,662.05. Following the transaction, the insider owned 169,269 shares in the company, valued at $2,012,608.41. The trade was a 2.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Kura Oncology Trading Up 4.3%

Kura Oncology stock traded up $0.51 during mid-day trading on Monday, hitting $12.40. 2,673,296 shares of the company’s stock were exchanged, compared to its average volume of 1,620,411. The company’s 50 day simple moving average is $10.53 and its 200-day simple moving average is $9.47. Kura Oncology, Inc. has a fifty-two week low of $7.36 and a fifty-two week high of $12.90. The company has a quick ratio of 4.71, a current ratio of 4.73 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.10 billion, a P/E ratio of -3.68 and a beta of 0.38.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.11. The firm had revenue of $20.87 million for the quarter, compared to analyst estimates of $20.16 million. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%. On average, equities analysts anticipate that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Kura Oncology during the second quarter valued at about $115,286,000. Suvretta Capital Management LLC increased its stake in Kura Oncology by 5.7% in the 4th quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after buying an additional 459,422 shares during the period. Vanguard Group Inc. lifted its position in Kura Oncology by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after purchasing an additional 39,105 shares during the period. Armistice Capital LLC increased its position in Kura Oncology by 5.7% during the 4th quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock worth $51,285,000 after purchasing an additional 264,000 shares during the period. Finally, State Street Corp boosted its stake in shares of Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after buying an additional 1,587,959 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have weighed in on KURA shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Sanford C. Bernstein set a $24.00 target price on Kura Oncology in a research note on Monday, June 15th. Oppenheimer set a $24.00 price target on Kura Oncology in a research note on Thursday, May 28th. Citigroup restated a “market outperform” rating on shares of Kura Oncology in a report on Monday. Finally, Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $25.40.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.